Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Total Debt (2021 - 2025)

Ascendis Pharma A (ASND) has disclosed Total Debt for 5 consecutive years, with $895.2 million as the latest value for Q4 2025.

  • Quarterly Total Debt rose 1.75% to $895.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $895.2 million through Dec 2025, up 1.75% year-over-year, with the annual reading at $895.2 million for FY2025, 1.75% up from the prior year.
  • Total Debt hit $895.2 million in Q4 2025 for Ascendis Pharma A, up from $879.8 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $895.2 million in Q4 2025 to a low of $120.1 million in Q4 2021.
  • Historically, Total Debt has averaged $548.5 million across 5 years, with a median of $440.2 million in 2023.
  • Biggest five-year swings in Total Debt: surged 239.19% in 2022 and later rose 1.75% in 2025.
  • Year by year, Total Debt stood at $120.1 million in 2021, then soared by 239.19% to $407.3 million in 2022, then increased by 8.08% to $440.2 million in 2023, then skyrocketed by 99.86% to $879.8 million in 2024, then increased by 1.75% to $895.2 million in 2025.
  • Business Quant data shows Total Debt for ASND at $895.2 million in Q4 2025, $879.8 million in Q4 2024, and $440.2 million in Q4 2023.